This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why it is Prudent for Investors to Hold Humana Stock for Now
by Zacks Equity Research
HUM remains well-poised for growth, attributable to improved premiums, contract wins, acquisitions, collaborations and growing cash reserves.
Will UNH, HUM & CVS be the Top Beneficiaries of the $21B MA Boom?
by Kaibalya Pravo Dey
The government's payment rate directly impacts insurers' pricing, plan benefits and overall profitability.
UnitedHealth Group (UNH) Beats Q4 Earnings Estimates
by Zacks Equity Research
UnitedHealth (UNH) delivered earnings and revenue surprises of 1.49% and 1.41%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Company News for Jan 15, 2025
by Zacks Equity Research
Companies in The News Are: KBH, BA, SHEL, HUM
Bet on 5 Top-Ranked Stocks With Rising P/E for Soild Gains
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Land's End, Humana, Rent the Runway, Becton, Dickinson and Company and ATI.
Should Value Investors Buy Humana (HUM) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Stock Market News for Jan 14, 2025
by Zacks Equity Research
Wall Street closed mixed on Monday, driven by energy and healthcare stocks.
Big Gains Ahead for Medicare Advantage Sellers as Payments Set to Grow
by Kaibalya Pravo Dey
As the largest MA plan sellers, UnitedHealth, Humana and CVS Health collectively account for nearly 60% of the market.
UnitedHealth Stock Q4 Earnings Preview: Buy Now or Wait for Results?
by Kaibalya Pravo Dey
UNH's fourth-quarter earnings are likely to have benefited from growing premiums and service revenues.
Zacks Industry Outlook Highlights UnitedHealth, Humana and Centene
by Zacks Equity Research
UnitedHealth, Humana and Centene have been highlighted in this Industry Outlook article.
3 HMO Stocks Poised to Thrive Despite Industry Headwinds
by Debasmita Chatterjee
The Medical-HMO industry benefits from a growing customer base and contract wins. However, industry challenges like rising costs and workforce shortages remain a concern. UNH, HUM and CNC are likely to navigate industry storms.
Cigna Stock Plunges 18.7% in 3 Months: Should You Buy, Hold or Sell?
by Zacks Equity Research
Despite market challenges, CI's strong fundamentals and growth drivers make it worth holding for long-term investors looking to capitalize on future recovery opportunities.
Healthcare Executives Bullish on 2025: But Why Are Stocks Slipping?
by Kaibalya Pravo Dey
Improving the consumer experience, engagement and trust is emerging as a top strategy for healthcare companies.
Company News for Dec 18, 2024
by Zacks Equity Research
Companies in The News Are: HUM, AMTM, DVN, TMUS
UnitedHealth 2025 Outlook Clouded by Heartbreaking Loss of Key Leader
by Zacks Equity Research
UNH expects 2025 operating cash flows to be within $32-$33 billion.
Humana (HUM) Up 15.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Recalculation Ahead: Implications of UnitedHealth's Win Against CMS
by Kaibalya Pravo Dey
UNH's success marks the third recent defeat for CMS in star ratings lawsuits, raising hopes for Humana and Centene as they challenge their own ratings.
UnitedHealth Stock Up 12.7% YTD: Is its Premium Valuation Justified?
by Kaibalya Pravo Dey
UNH and the broader health insurance industry will likely focus on cost-cutting initiatives and lobbying for better government reimbursement rates over time.
Elevance Health Declines 20% in 3 Months: Time to Sell the Stock?
by Debasmita Chatterjee
ELV encounters headwinds such as higher benefit costs, an increased debt level and member attrition in the Medicaid business, which raise concerns among investors.
Cigna Ends Humana Merger Speculation: CI Jumps 7.3% While HUM Slips
by Zacks Equity Research
CI reaffirms its 2024 outlook, projecting full-year adjusted EPS to be a minimum of $28.40.
Stocks and ETFs in Focus as Americans Head to Polls
by Sweta Killa
Let's discuss the sectors and ETFs that are the potential gainers or losers as Americans head to the polls, which indicate a tight race between Harris and Trump.
Humana Q3 Earnings Beat on Growing Premiums & Cost Management
by Zacks Equity Research
Better-than-expected Medicare Advantage membership aids HUM's third-quarter results.
Compared to Estimates, Humana (HUM) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Humana (HUM) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Humana (HUM) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 19.54% and 2.24%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Higher Expense Level Be a Woe for Humana in Q3 Earnings?
by Zacks Equity Research
HUM's Q3 results are likely to suffer from decline in commercial fully-insured premiums and higher operating costs, partly offset by a well-performing Medicare business.